文献速递肿瘤 PET/CT

钙网蛋白显像用于抗癌治疗中免疫原性细胞死亡的早期检测

Imaging Calreticulin for Early Detection of Immunogenic Cell Death During Anticancer Treatment.
PubMed 文献 · J Nucl Med · 2021-01-28

研究评估了钙网蛋白特异性结合肽(CRTpep)在免疫原性细胞死亡过程中对细胞表面暴露钙网蛋白(ecto-CRT)的显像效果。体外流式细胞术、免疫荧光染色及体内小动物PET显像显示,CRTpep可检测免疫原性药物或放射治疗诱导的凋亡前细胞,而非免疫原性药物或无治疗剂量免疫原性药物处理的细胞则不能被检测。结果表明CRT特异性肽有助于预测治疗反应,从而辅助早期决定免疫原性治疗的继续或停止。

要点

  • CRTpep可特异性识别免疫原性药物或放射治疗诱导的凋亡前细胞表面的ecto-CRT。
  • 18F标记CRTpep的小动物PET显像可在体内检测ecto-CRT。
  • 该探针有望早期预测免疫原性治疗反应,辅助治疗决策。

核心结论

  • CRT特异性肽可检测免疫原性细胞死亡过程中的ecto-CRT,有望预测治疗反应并辅助早期治疗决策。

研究设计与样本

  • 合成CRT特异性肽KLGFFKR(CRTpep),用异硫氰酸荧光素或18F标记,在结肠癌细胞系中行体外和体内评价。

主要发现

  • 体外流式细胞术、免疫荧光染色及体内小动物PET显像显示,CRTpep可检测免疫原性药物或放射治疗处理的凋亡前细胞。
  • CRTpep不能检测非免疫原性药物或无治疗剂量免疫原性药物处理的细胞。

临床怎么用

  • CRTpep显像或可用于免疫原性抗癌治疗早期预测治疗反应,辅助决定继续或停止免疫原性治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Surface-exposed calreticulin (ecto-CRT) is a well-known "eat-me" signal exhibited by dying cells that contributes to their recognition and destruction by the immune system. We assessed the use of a CRT-specific binding peptide for imaging ecto-CRT during immunogenic cell death and its utility for early prediction of treatment response. Methods: A synthetic CRT-specific peptide, KLGFFKR (CRTpep), was labeled with fluorescein isothiocyanate or 18F, and the characteristics of ecto-CRT were evaluated in a colon cancer cell line in vitro and in vivo. Results: In vitro flow cytometry, immunofluorescence staining, and in vivo small-animal PET imaging results showed that CRTpep detected preapoptotic cells treated with immunogenic drugs or radiation but not those treated with the nonimmunogenic drug or a nontherapeutic dose of immunogenic drug. Conclusion: The present results indicate that the CRT-specific peptide would enable the prediction of therapeutic response, thereby facilitating early decisions on continuation or discontinuation of immunogenic treatment.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kim DY, Pyo A, Yun M, et al. Imaging Calreticulin for Early Detection of Immunogenic Cell Death During Anticancer Treatment. J Nucl Med. 2021. PMID: 33509975. doi:10.2967/jnumed.120.245290

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。